Directory
Jose Manuel Valdivielso Revilla

Jose Manuel Valdivielso Revilla

Degree: PhD

973 702 952
valdivielso(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/B-5673-2009

Groups

Publications

  • Crespo-Masip, M; Perez-Gomez, A; Guzman, C; Rayego, S; Dolade, N; Garcia-Carrasco, A; Jover, R; Valdivielso, JM

    PTEN Deletion in Adult Mice Induces Hypoinsulinemia With Concomitant Low Glucose Levels.

    Frontiers in Endocrinology 13 850214-850214. .

    [doi:10.3389/fendo.2022.850214]

  • Núñez E; Fuster, V; Gomez-Serrano, M; Valdivielso, JM; Fernandez-Alvira, JM; Martinez-Lopez, D; Rodriguez, JM; Bonzon-Kulichenko, E; Calvo, E; Alfayate, A; Bermudez-Lopez, M; Escola-Gil, JC; Fernandez-Friera, L; Cerro-Pardo, I; Mendiguren, JM; Sanchez-Cabo, F; Sanz, J; Ordovas, JM; Blanco-Colio, LM; Garcia-Ruiz, JM; Ibáñez B; Lara-Pezzi, E; Fernandez-Ortiz, A; Martin-Ventura, JL; Vazquez, J

    Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis.

    EBioMedicine 76 103874-103874. .

    [doi:10.1016/j.ebiom.2022.103874]

  • Mota-Zamorano S; González LM; Robles NR; Valdivielso JM; Cancho B; López-Gómez J; Gervasini G

    A Custom Target Next-Generation Sequencing 70-Gene Panel and Replication Study to Identify Genetic Markers of Diabetic Kidney Disease.

    Genes 12 -. .

    [doi:10.3390/genes12121992]

  • Bermúdez-López M; Martínez-Alonso M; Castro-Boqué E; Betriu À; Cambray S; Farràs C; Barbé F; Pamplona R; Lecube A; Mauricio D; Purroy F; Valdivielso JM; Fernández E; ILERVAS project collaborators

    Subclinical atheromatosis localization and burden in a low-to-moderate cardiovascular risk population: the ILERVAS study.

    REVISTA ESPANOLA DE CARDIOLOGIA 74 1042-1053. .

    [doi:10.1016/j.rec.2020.09.015]

  • Bermudez-Lopez M; Perpiñan H; Amigo N; Castro E; Alonso N; Mauricio D; Fernandez E; Valdivielso JM

    Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients.

    CLINICAL KIDNEY JOURNAL 14 2591-2599. .

    [doi:10.1093/ckj/sfab113]

  • Solache-Berrocal G; Rolle-Sóñora V; Martín-Fernández N; Cambray S; Valdivielso JM; Rodríguez I

    CYP24A1 and KL polymorphisms are associated with the extent of vascular calcification but do not improve prediction of cardiovascular events.

    NEPHROLOGY DIALYSIS TRANSPLANTATION 36 2076-2083. .

    [doi:10.1093/ndt/gfaa240]

  • Valdivielso JM; Balafa O; Ekart R; Ferro CJ; Mallamaci F; Mark PB; Rossignol P; Sarafidis P; Del Vecchio L; Ortiz A

    Correction to: Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies.

    DRUGS 81 1819-1819. .

    [doi:10.1007/s40265-021-01617-8]

  • Castelblanco E; Sarrias MR; Betriu À; Soldevila B; Barranco-Altirriba M; Franch-Nadal J; Valdivielso JM; Bermudez-Lopez M; Groop PH; Fernández E; Alonso N; Mauricio D

    Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease.

    Aging-US 13 22690-22709. .

    [doi:10.18632/aging.203615]

  • Alonso-Perez E; Forné C; Soro M; Valls M; Manganelli AG; Valdivielso JM

    Health Care Costs in Patients with and without Secondary Hyperparathyroidism in Spain.

    Advances in Therapy 38 5333-5344. .

    [doi:10.1007/s12325-021-01895-4]

  • Mota-Zamorano S; Robles NR; González LM; Valdivielso JM; Lopez-Gomez J; Cancho B; García-Pino G; Gervasini G

    Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy.

    Journal of Clinical Medicine 10 -. .

    [doi:10.3390/jcm10173980]

  • Valdivielso, JM; Balafa, O; Ekart, R; Ferro, CJ; Mallamaci, F; Mark, PB; Rossignol, P; Sarafidis, P; del Vecchio, L; Ortiz, A

    Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies

    DRUGS 81 1467-1489. .

    [doi:10.1007/s40265-021-01555-5]

  • González LM; Robles NR; Mota-Zamorano S; Valdivielso JM; López-Gómez J; Gervasini G

    Genetic Variants in PGE2 Receptors Modulate the Risk of Nephrosclerosis and Clinical Outcomes in These Patients.

    Journal of Personalized Medicine 11 -. .

    [doi:10.3390/jpm11080772]

Projects

  • Estancias de personal docente y/o investigador senior en centros extranjeros 2022
  • El primer Estudio de asociación de genoma completo (GWAS) con enfermedad coronaria poblacional a 10 años en más de 100.000 participantes para personalizar la prevención cardiovascular en España
  • Influence of SARS-COV-2 infection in atherosclerosis development. “El BUS DE LA SALUT” study
  • SPAIN CKD CAUSE (SPACKDC)
  • INVESTIGO 2022: Grup de recerca translacional vascular i renal
  • Papel de PTEN en la reabsorcion tubular renal de proteinas. Implicaciones en nefropatias proteinuricas
  • Preservació la membrana peritoneal abordant noves vies per inhibir la transició mesotelio-mesenquimal.
  • Acciones de Dinamización "Europa Investigación 2020"
  • Contratos Sara Borrell
  • Papel de la vía PI3K/AKT/mTOR en la regulación de las alteraciones del metabolismo mineral en la enfermedad renal crónica. Implicaciones en la regulación de la síntesis de FGF23.
  • Ajuts destinats a contractar personal investigador novell (FI)
  • CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA CIENTIFICA BASICA PER A LA CARACTERITZACIO D'UN PERFIL LIPIDOMICO Y LIPIDICO DE RIESGO ATEROGENERICO Y DE MORBIMORTALIDAD CARDIOVASCUAL EN LA ENFERMEDAD RENAL CRONICA (ESTADIOS 3 A 5), ESTUDIO PROSPECTIVO NEFRONA.